Baldwin Chris E, Berkhout Ben
Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center of the University of Amsterdam, The Netherlands.
Retrovirology. 2006 Nov 29;3:84. doi: 10.1186/1742-4690-3-84.
We previously described the selection of a T20-dependent human immunodeficiency virus type-1 (HIV-1) variant in a patient on T20 therapy. The fusion inhibitor T20 targets the viral envelope (Env) protein by blocking a conformational switch that is critical for viral entry into the host cell. T20-dependent viral entry is the result of 2 mutations in Env (GIA-SKY), creating a protein that undergoes a premature conformational switch, and the presence of T20 prevents this premature switch and rescues viral entry. In the present study, we performed 6 independent evolution experiments with the T20-dependent HIV-1 variant in the absence of T20, with the aim to identify second site compensatory changes, which may provide new mechanistic insights into Env function and the T20-dependence mechanism.
Escape variants with improved replication capacity appeared within 42 days in 5 evolution cultures. Strikingly, 3 cultures revealed the same single amino acid change in the CD4 binding region of Env (glycine at position 431 substituted for arginine: G431R). This mutation was sufficient to abolish the T20-dependence phenotype and restore viral replication in the absence of T20. The GIA-SKY-G431R escape variant produces an Env protein that exhibits reduced syncytia formation and reduced cell-cell fusion activity. The escape variant was more sensitive to an antibody acting on an early gp41 intermediate, suggesting that the G431R mutation helps preserve a pre-fusion Env conformation, similar to T20 action. The escape variant was also less sensitive to soluble CD4, suggesting a reduced CD4 receptor affinity.
The forced evolution experiments indicate that the premature conformational switch of the T20-dependent HIV-1 Env variant (GIA-SKY) can be corrected by a second site mutation in Env (GIA-SKY-G431R) that affects the interaction with the CD4 receptor.
我们之前描述了在接受T20治疗的患者中选择出的一种依赖T20的1型人类免疫缺陷病毒(HIV-1)变体。融合抑制剂T20通过阻断对病毒进入宿主细胞至关重要的构象转换来靶向病毒包膜(Env)蛋白。依赖T20的病毒进入是Env中两个突变(GIA-SKY)的结果,产生了一种经历过早构象转换的蛋白,而T20的存在可防止这种过早转换并挽救病毒进入。在本研究中,我们在不存在T20的情况下对依赖T20的HIV-1变体进行了6次独立的进化实验,目的是识别第二位点补偿性变化,这可能为Env功能和T20依赖机制提供新的机制性见解。
在5种进化培养物中,具有改善复制能力的逃逸变体在42天内出现。引人注目的是,3种培养物在Env的CD4结合区域显示出相同的单氨基酸变化(第431位的甘氨酸被精氨酸取代:G431R)。该突变足以消除T20依赖表型,并在不存在T20的情况下恢复病毒复制。GIA-SKY-G431R逃逸变体产生的Env蛋白表现出减少的合胞体形成和降低的细胞-细胞融合活性。该逃逸变体对作用于早期gp41中间体的抗体更敏感,表明G431R突变有助于维持融合前Env构象,类似于T20的作用。该逃逸变体对可溶性CD4也较不敏感,表明CD4受体亲和力降低。
强制进化实验表明,依赖T20的HIV-1 Env变体(GIA-SKY)的过早构象转换可通过Env中的第二位点突变(GIA-SKY-G431R)来纠正,该突变影响与CD4受体的相互作用。